Publications by authors named "Su-Pin Choo"

Claim this Profile
H
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population.
Jing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, Zi Yi Wan, Donald Poon, Su Pin Choo

NPJ Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma.
Kennedy Yao Yi Ng, Albert Eng Keong Teo, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Su Pin Choo

Asia Pac J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.
Neslihan Arife Kaya, David Tai, Xinru Lim, Jia Qi Lim, Mai Chan Lau, Su Pin Choo

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Kennedy Yao Yi Ng, Lawrence Wen Jun Wong, Andrea Jing Shi Ang, Ailica Wan Xin Lee, Desiree Shu Hui Tay, Su Pin Choo

Asia Pac J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
Chun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, Nicole Hyacinth Calpatura Orpilla, Mai Chan Lau, Su Pin Choo

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore.
Wei Peng Yong, Felicia Sw Teo, Lynette Ls Teo, Matthew Ch Ng, Tira J Tan, Su Pin Choo

Expert Opin Drug Metab Toxicol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.
Florian Kocher, Alberto Puccini, Gerold Untergasser, Agnieszka Martowicz, Kai Zimmer, Su-Pin Choo

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Samuel Chuah, Joycelyn Lee, Yuan Song, Hyung-Don Kim, Martin Wasser, Su Pin Choo

J Hepatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
Thomas Yau, David Tai, Stephen Lam Chan, Yi-Hsiang Huang, Su Pin Choo

Liver Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial.
Stephen Lam Chan, Chanisa Chotipanich, Su Pin Choo, Su Wen Kwang, Frankie Mo

Liver Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Kiat Hon Tony Lim, Hwai Loong Kong, Kenneth Tou En Chang, Daniel Shao Weng Tan, Iain Bee Huat Tan, Su Pin Choo

Asia Pac J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Matthew Ng, Sylvia Chen, Whee Sze Ong, Akhila Balachander, Amanda Seet, Su Pin Choo

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Raghav Sundar, Kie-Kyon Huang, Vikrant Kumar, Kalpana Ramnarayanan, Deniz Demircioglu, Su Pin Choo

Gut· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo

J Exp Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and bevacizumab for HCC in the real world.
Su Pin Choo, Pierre Nahon

Liver Int· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Amanda O L Seet, Aaron C Tan, Tira J Tan, Matthew C H Ng, David W M Tai, Su Pin Choo

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Su Pin Choo

Lancet Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Su Pin Choo

Liver Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
David Tai, Kelvin Loke, Apoorva Gogna, Neslihan Arife Kaya, Sze Huey Tan, Choon Hua Thng, Su Pin Choo

Lancet Gastroenterol Hepatol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Su Pin Choo

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Su-Pin Choo

J Hepatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Yang Cheng, Bavani Gunasegaran, Harsimran D Singh, Charles-Antoine Dutertre, Chiew Yee Loh, Su Pin Choo

Immunity· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma.
Xin Hui Chew, Rehena Sultana, Eshani N Mathew, David Chee Eng Ng, Richard H G Lo, Su Pin Choo, Choon Hua Thng

Liver Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
Sadahisa Ogasawara, Su-Pin Choo, Jiang-Tao Li, Changhoon Yoo, Bruce Wang

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis